Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

被引：36
|
作者：
Wang, Zhan [1 ]
Chen, Juan [2 ,3 ]
Zhong, Mei-Zuo [1 ]
Huang, Juan [4 ]
Hu, Yuan-Ping [4 ]
Feng, De-Yun [5 ]
Zhou, Zhi-Jiao [6 ]
Luo, Xiao [7 ]
Liu, Zhao-Qian [2 ,3 ]
Jiang, Wu-Zhong [1 ]
Zhou, Wei-Bing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Clin Meditech Res Ctr Breast Canc, Changsha 410008, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Pathol, Changsha 410013, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Dept Pain, Changsha 410013, Hunan, Peoples R China
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 79卷 / 03期
基金：
中国国家自然科学基金;
关键词：
ANLN; Breast cancer; Anthracycline; Prognosis; BINDING PROTEIN ANILLIN; DNA ADDUCTS; CYCLIN D1; ADJUVANT THERAPY; DOXORUBICIN; REPAIR; CYCLOPHOSPHAMIDE; EXPRESSION; RECOMBINATION; ACTIVATION;
D O I：
10.1007/s00280-017-3248-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
引用
收藏
页码：535 / 543
页数：9
相关论文
共 50 条
  • [31] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy
    Wafaa S. El-Sherbeny
    Nesreen M. Sabry
    Radwa M. Sharbay
    Journal of Echocardiography, 2019, 17 : 76 - 83
  • [32] Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
    Chirivella, Isabel
    Bermejo, Begona
    Insa, Amelia
    Perez-Fidalgo, Alejandro
    Magro, Ana
    Rosello, Susana
    Garcia-Garre, Elisa
    Martin, Paloma
    Bosch, Ana
    Lluch, Ana
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 479 - 484
  • [33] Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review
    Simoes, Ricardo
    Silva, Luciana Maria
    Valle Mussi Cruz, Andre Luiz
    Fraga, Vanessa Gomes
    Sabino, Adriano de Paula
    Gomes, Karina Braga
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 : 989 - 996
  • [34] Longitudinal rotation: a new way to detect the cardiotoxicity of anthracycline-based chemotherapy in breast cancer patients
    Huang, Jun
    Yan, Zi-Ning
    Rui, Yi-Fei
    Shen, Dan
    Fan, Li
    Chen, Dong-Liang
    ONCOTARGET, 2017, 8 (41) : 70072 - 70083
  • [35] Late cardiotoxicity in patients with breast cancer after taxane/anthracycline-based neoadjuvant and adjuvant chemotherapy
    Koroleva, I.
    Kopp, M. V.
    Kasulin, A. N.
    Kucheryavyy, J. A.
    Byakhov, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Fragmented QRS formation and its predictors in patients with breast cancer receiving anthracycline-based chemotherapy
    Dural, Muhammet
    Demir, Lutfiye
    Babayigit, Erdi
    Junushova, Bermet
    Mert, Kadir Ugur
    Ulus, Taner
    Cavusoglu, Yuksel
    Yildiz, Bulent
    Dincer, Murat
    Gorenek, Bulent
    JOURNAL OF ELECTROCARDIOLOGY, 2019, 54 : 5 - 9
  • [37] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy
    El-Sherbeny, Wafaa S.
    Sabry, Nesreen M.
    Sharbay, Radwa M.
    JOURNAL OF ECHOCARDIOGRAPHY, 2019, 17 (02) : 76 - 83
  • [38] Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy
    Mendonca, M. A. O.
    Pereira, A. H. M.
    Silva, S. R.
    Mardegan, M. C.
    Murta, E. F. C.
    Tavares-Murta, B. M.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (02) : 184 - 190
  • [39] Clinical and echocardiographic characteristics of female patients with breast cancer treated with anthracycline-based combined chemotherapy
    Spannbauer, A.
    Han, E.
    Gramser, A.
    Gyoengyoesi, M.
    Bergler-Klein, J.
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (SUPPL 2) : 196 - 197
  • [40] Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
    Isabel Chirivella
    Begoña Bermejo
    Amelia Insa
    Alejandro Pérez-Fidalgo
    Ana Magro
    Susana Rosello
    Elisa García-Garre
    Paloma Martín
    Ana Bosch
    Ana Lluch
    Breast Cancer Research and Treatment, 2009, 114 : 479 - 484
12345